Eli Lilly (LLY)

The stock recently reached beyond $1,000.

New York, NY – November 26, 2025 – U.S. stock markets are surging, with Wall Street poised to extend a remarkable winning streak as investors enthusiastically price in aggressive interest rate cuts by the Federal Reserve. This newfound optimism, particularly evident in the days leading up to November 26, 2025, has

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Companies and investors see AI as a game-changing technology.

The weight loss drug market may approach almost $100 billion by the end of the decade.

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.

Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not.

Good news from a GLP-1 receptor agonist clinical trial hit the market today.

As November 25, 2025, unfolds, financial markets find themselves at a critical juncture, gripped by a pervasive debate that pits optimists against skeptics: are current market pullbacks merely a "Buy The Dip" opportunity, or do they herald the onset of a more protracted "Bear Market"? This question hangs heavy in

Though UnitedHealth Group has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.

The US stock market as of late November 2025 presents a nuanced landscape of resilience and apprehension. While major indices have enjoyed robust year-to-date gains, largely propelled by the relentless surge in artificial intelligence (AI) innovation, the market has recently succumbed to heightened volatility. Investor sentiment is a delicate balance

Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement of disappointing results from its highly anticipated late-stage clinical trials for an Alzheimer's disease drug. The trials, which tested an oral formulation

Eli Lilly fell while Biogen jumped.

Investing in an S&P 500 index fund can be a great way to build long-term wealth.

Eli Lilly (LLY) presents strong growth at a reasonable price (GARP), with accelerating earnings and revenue supported by top-tier profitability.

After a bruising week, Wall Street regained its footing on Friday as rate-cut hopes resurfaced and fears around the AI sell-off eased, if only slightly. Solid PMI data and improving inflation expectations helped stabilize sentiment.

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Merck (NYSE:MRK) and the best and worst performers in the branded pharmaceuticals industry.

These Magnificent Seven players are well-positioned to benefit in the AI boom.

Who says you have to choose between the two?